The present disclosure concerns uses for isoxazole compounds or salts or analogs thereof for the treatment of wounds. The present disclosure also concerns devices for delivering a isoxazole compound or salts or an analogs thereof to a wound site.

The present disclosure concerns drug coating layers for medical devices that cover an exterior surface or portion thereof. The drug coating layers include a bioabsorbable material with a therapeutic or a polymer microparticle loaded with a therapeutic embedded therein. As the material is bioabsorbed the therapeutic is released and available to provide localized activity in a subject. In some aspects, the drug coating layer is of a material that due to the body temperature of the subject becomes tacky and allows for adhesion to the vessel wall.

In a halloysite-based composite hemostatic material, hydroxylated halloysite is used as a carrier, and the carrier is loaded with aggregation-induced emission (AIE) nanoparticles. The preparation method includes: preparing the hydroxylated halloysite into a hydroxylated halloysite suspension; preparing the AIE nanoparticles into an AIE nanoparticle solution; and thoroughly mixing the hydroxylated halloysite suspension with the AIE nanoparticle solution at a specified temperature and a specified oscillation speed, centrifuging a resulting mixed solution, and lyophilizing a resulting precipitate to obtain an AIE nanoparticles-loaded modified halloysite composite, which is the halloysite-based composite hemostatic material. The surface-hydroxylated halloysite is used to significantly improve a hemostatic effect; and the AIE nanoparticles is functionally loaded at a small amount to further improve hemostatic properties in addition to endowing the halloysite with an antibacterial activity, so as to finally obtain the halloysite-based composite hemostatic material with excellent biocompatibility, high safety, and a prominent antibacterial effect.

Described herein are antibacterial nanoparticles composed of a porphyrin and a nitric oxide donor. In one aspect, the antibacterial nanoparticles are produced by the method comprising (a) admixing a porphyrin with glutathione or a pharmaceutically acceptable salt or ester thereof to produce a first compound and (b) reacting the first compound with a nitric oxide compound, wherein the nitric oxide compound forms a covalent bond with glutathione or the pharmaceutically acceptable salt or ester. The antibacterial nanoparticles are dynamic in their ability to specifically target pathogenic infections while remaining nontoxic towards mammalian cells and can also be used as medical device coatings to prevent infections as well as in treatment and management of diseases like cancer and autoimmune skin disorders.

Described are polymers and methods of forming and using same.

Biodegradable, cross-linked polymer particle embolics and methods of making the same are described. The particle embolics can be used as embolization agents.

The present invention relates to the contacting of one or more surfaces of an implantable medical device with one or more diketopiperazines (DKPs).

Compositions and methods for the surface appearance of the skin a subject are provided. An injectable composition comprising at least hyaluronic acid or a salt thereof; and an effective amount of at least mepivacaine or a salt thereof are provided. The hyaluronic acid optionally has an average molecular weight ranging from 50,000 to 10,000,000 Daltons, and may be crosslinked hyaluronic acids, non-crosslinked hyaluronic acids, or a combination, in some embodiments. The compositions and methods of the present invention are useful for treating and preventing the cutaneous signs of chronological aging and/or induced by external factors such as stress, air pollution, tobacco or prolonged exposure to ultraviolet (UV) exposure, impaired surface appearance of the skin, impaired viscoelastic or biomechanical properties of the skin, and/or the long-lasting filling of volume defects of the skin.

The disclosure provides hyaluronic acid (HA) gel formulations and methods for treating the appearance of the skin. The formulations contain hyaluronic acid and at least one additional ingredient. Methods for treating lines, wrinkles, fibroblast depletions, and scars with the disclosed composition are provided as well.

The present invention relates to treating or preventing stenosis at an anastomosis site. In one embodiment, the present invention is a stent is curved along the longitudinal axis for placement in and adjacent to the graft orifice. In a further embodiment, the stent is drug coated to allow delivery of antivasculoproliferative drugs directly to the vicinity of the graft orifice. In a further embodiment, the stent is expandable by use of an external wire. In another embodiment, the present invention is a kit comprising the specially configured stent together with a sleeve comprising a biocompatible matrix material and a pharmaceutical agent, wherein the sleeve is applied to the external surface of the vessel or graft, resulting in extravascular delivery of a pharmaceutical agent. Methods for treating or preventing stenosis at an anastomosis site by applying the extravascular sleeve and the intravascular stent are also provided.